Neuroendocrine Carcinoma Market Size, Share & Trends Analysis Report By Product

 Focused on real-world business use, this report highlights what’s changing in the neuroendocrine carcinoma market and what companies should prepare for next.

 

 What Is The Current Outlook For The Neuroendocrine Carcinoma Market By 2025?
 The neuroendocrine carcinoma market size has grown strongly in recent years. It will grow from $1.63 billion in 2024 to $1.75 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to the rise of the imaging sector, an increase in the incidence of neuroendocrine tumors, increasing investments, increasing government initiatives, and demand for treatments for neuroendocrine tumors.
 
 The neuroendocrine carcinoma market size is expected to see strong growth in the next few years. It will grow to $2.31 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to the increasing incidence rate of cancer disease, increasing rate of product approval, rising usage of improved diagnostic imaging methods, growth of targeted therapies, and increasing rate of diagnosis and treatment options available. Major trends in the forecast period include the advancement in diagnostic technologies, enhanced imaging technologies, targeted treatment approaches, advancements in neuroendocrine tumor management, and the advancement in targeted therapies and immunotherapies.
 
 Get your free sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=21229&type=smp
 
 What Are The Key Driving Factors For The Growth Of The Neuroendocrine Carcinoma Market?
 The growth of targeted therapies is expected to propel the growth of the neuroendocrine carcinoma market going forward. Targeted therapies are treatments designed to precisely address and disrupt the molecular processes or genetic alterations that cause a disease, especially cancer. The demand for targeted therapies rises due to factors such as their precision in treating specific genetic mutations, advancements in personalized medicine, and better patient outcomes with fewer side effects. Neuroendocrine carcinoma enables the development of targeted therapies that specifically address the tumor’s genetic and biochemical profiles, enhancing treatment precision and effectiveness. For instance, in July 2023, according to the report published by the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, at the end of Q1 2023, there were 247 gene therapies in Phase II, but this number rose by 5% to reach 260 by the end of Q2. Therefore, the growth of targeted therapies is driving the growth of the neuroendocrine carcinoma market.
 
 Global Neuroendocrine Carcinoma Market Report Segmentation
 The neuroendocrine carcinomamarket covered in this report is segmented — 
 
 1) By Type: Gastroenteropancreatic Neuroendocrine Tumors; Carcinoid Tumors; Pheochromocytoma; Medullary Thyroid Carcinoma
 2) By Diagnostic Tools: Imaging; Biopsy; Serology
 3) By Treatment: Chemotherapy; Radiotherapy; Surgery; Other Treatments
 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
 5) By End-User: Hospitals; Clinics; Oncology Centers; Ambulatory Surgery Centers
 
 Subsegments:
 1) By Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Pancreatic Neuroendocrine Tumors (pNETs); Small Intestinal Neuroendocrine Tumors; Gastric Neuroendocrine Tumors; Colorectal Neuroendocrine Tumors 
 2) By Carcinoid Tumors: Pulmonary Carcinoid Tumors; Gastrointestinal Carcinoid Tumors 
 3) By Pheochromocytoma: Adrenal Pheochromocytoma; Extra-Adrenal Paraganglioma 
 4) By Medullary Thyroid Carcinoma: Sporadic Medullary Thyroid Carcinoma; Hereditary Medullary Thyroid Carcinoma (MEN2-Associated)
 
 What Are The Key Trends And Market Opportunities In The Neuroendocrine Carcinoma Sector?
 Major companies operating in the neuroendocrine carcinoma market are focusing on developing advanced therapies, such as targeted radiopharmaceutical therapy, to improve treatment precision and patient outcomes. Targeted radiopharmaceutical therapy involves using radioactive molecules that specifically target and deliver radiation to cancer cells, minimizing harm to healthy tissue. For instance, in September 2024, Abdera Therapeutics Inc., a Canada-based biotechnology company, received the Food and Drug Administration (FDA)-granted orphan drug designation for ABD-147 for the treatment of neuroendocrine carcinoma. It is designed to selectively target tumors expressing the DLL3 protein, commonly upregulated in aggressive neuroendocrine cancers such as small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). This designation offers significant development advantages, including tax credits for clinical trials and the potential for market exclusivity, positioning ABD-147 as a promising treatment in this specialized oncology space.
 
 Who Are The Leading Players In The Neuroendocrine Carcinoma Market?
 Major companies operating in the neuroendocrine carcinoma market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Amgen Inc., Boehringer Ingelheim GmbH, Exelixis Inc., Lantheus Holdings Inc., HUTCHMED Limited, Dana-Farber Cancer Institute Inc., Abdera Therapeutics Inc., Orano Med S.A, Eckert & Ziegler Radiopharma GmbH, Callisto Pharmaceuticals Inc., RadioMedix Inc., Clarity Pharmaceuticals Limited, Delcath Systems Inc., Provectus Biopharmaceuticals Inc. 
 
 View the full neuroendocrine carcinoma market report here:
 https://www.thebusinessresearchcompany.com/report/neuroendocrine-carcinoma-global-market-report
 
 Which Region Is Projected To Hold The Largest Market Share In The Global Neuroendocrine Carcinoma Market By 2029?
 North America was the largest region in the neuroendocrine carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroendocrine carcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company